ADC for SCLC Clears Phase I

ZL-1310, an antibody-drug conjugate that targets DLL3-expressing small cell lung cancer cells, led to responses in nearly half of patients in a phase I study. These results provide further evidence that targeting DLL3 may be a promising approach for treating this cancer.